Neutral
Banque Cantonale Vaudoise trimmed its holdings in Biogen Inc. (NASDAQ:BIIB – Free Report) by 77.1% in the 4th quarter, Holdings Channel reports. The f...
Bearish
A Parkinson's disease drug developed by Biogen and Denali Therapeutics, BIIB122, failed its mid-stage clinical trial, showing no significant improveme...
Bearish
Levi & Korsinsky, LLP has announced a securities fraud investigation into Biogen Inc. (BIIB) after the company's shares dropped approximately 6.4% on ...
Bullish
Shares of Biogen (NASDAQ: BIIB) fell over 10% after its Alzheimer's drug, diranersen, missed its primary endpoint in the Phase 2 CELIA trial. Despite ...
Neutral
Biogen and Denali Therapeutics have discontinued their investigational Parkinson's disease drug, BIIB122 (DNL151), for idiopathic Parkinson's after it...
SueWallSt is investigating Biogen Inc. (BIIB) for possible securities law violations after the company's Phase 2 "CELIA" trial for diranersen missed i...
Bearish
SueWallSt is investigating Biogen Inc. (NASDAQ: BIIB) for possible securities law violations after shares dropped 6.4% on May 14, 2026. This decline f...
Biogen has finalized its acquisition of Apellis Pharmaceuticals for $41.00 per share in cash, plus one contingent value right (CVR) offering up to an ...
Bullish
Biogen Inc. has announced the completion of its acquisition of Apellis Pharmaceuticals, making Apellis a wholly owned subsidiary. This acquisition sig...
Biogen has finalized the terms for a Contingent Value Right (CVR) of up to $4.00 per share tied to Apellis' SYFOVRE annual net sales milestones throug...
Apellis Pharmaceuticals has successfully concluded its tender offer, with approximately 82.4% of its outstanding shares tendered, allowing Biogen to p...
Bullish
Biogen has announced it will move its experimental Alzheimer's drug, diranersen, to late-stage trials despite it failing to meet the primary goal in a...
Bullish
Biogen (NASDAQ: BIIB) announced mixed but promising topline results from its Phase 2 CELIA study for diranersen, an investigational Alzheimer’s drug. ...
Bullish
Biogen announced compelling topline results from its Phase 2 CELIA study of diranersen (BIIB080) for early Alzheimer's disease. The study, while not m...
Neutral
The FDA has extended its priority review period for Eisai and Biogen's LEQEMBI® IQLIK™ subcutaneous injection for early Alzheimer's disease by three m...
Biogen Inc. reported a Q1 2026 earnings beat but issued lower full-year guidance due to increased R&D spending and pressure on older multiple sclerosi...
Bullish
Artemis Investment Management LLP has acquired 226,845 shares of Biogen Inc. (NASDAQ:BIIB) during the fourth quarter, valued at approximately $39.9 mi...
Biogen (BIIB) has seen a 51.7% return over the last year, with its share price closing at US$180.67. A Discounted Cash Flow (DCF) analysis suggests th...
Bullish
UBS has upgraded Biogen Inc. (BIIB) to Buy from Neutral, increasing its price target to $225, citing upcoming pipeline catalysts within the next 12-15...